Italy publishes notice changing marketing permission for Zestan
Italy's medicines agency AIFA published a notice on 3 November 2026 about a change to the marketing authorization for Zestan, a human medicine combining ezetimibe and simvastatin. Marketing authorization is the official permission that lets a medicine be sold. The excerpt does not say what the change is, so the details would be found in the full official notice.
This summary was generated by AI; the official source prevails.
What does it mean?
Zestan is a medicine that lowers cholesterol, and this notice means its official sales permission in Italy has been changed in some way. The excerpt does not say what changed. Anyone who uses or prescribes Zestan would need the full notice to see the details.
Who is affected?
Patients who take Zestan and the doctors and pharmacies that prescribe and dispense it.